Patients are at risk. A respected pharmacist is on the take. Robert Courtney mixes a prescription of greed... diluting life-saving drugs and the hopes of cancer patients.
Credit Suisse has an underperform rating on Sands China, with a target price of HK$8.50. Gabriel Chan, research analyst at Credit Suisse, explains the reasons behind this rating, with CNBC's Oriel Morrison & Emily Chan.